Close



Apr 26, 2021 07:33AM
Apr 26, 2021 07:30AM
Mar 25, 2021 05:20PM
Jul 11, 2019 08:01AM
Jul 11, 2019 08:00AM
Jul 2, 2019 04:15PM
May 10, 2019 08:00AM BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
May 9, 2019 04:05PM
May 6, 2019 08:00AM
May 2, 2019 08:22AM
May 2, 2019 08:00AM
Apr 26, 2019 08:00AM
Mar 15, 2019 09:25AM
Mar 14, 2019 04:05PM BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Mar 11, 2019 08:00AM
Nov 8, 2018 06:35AM
Aug 2, 2018 04:05PM
Jul 25, 2018 07:00AM
Jun 25, 2018 07:00AM
May 29, 2018 07:05AM
May 29, 2018 07:00AM BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
May 24, 2018 07:00AM
May 10, 2018 04:05PM
May 1, 2018 08:00AM
Apr 16, 2018 07:00AM
Apr 9, 2018 08:00AM
Mar 15, 2018 04:05PM
Mar 7, 2018 08:00AM BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
Feb 15, 2018 07:00AM
Jan 22, 2018 07:00AM
Jan 17, 2018 07:08AM
Jan 17, 2018 07:00AM
Dec 4, 2017 08:06AM
Dec 4, 2017 08:00AM
Nov 15, 2017 08:01AM BioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data
Nov 15, 2017 08:00AM
Nov 9, 2017 04:05PM
Oct 11, 2017 08:59AM
Oct 11, 2017 07:06AM
Oct 11, 2017 07:00AM
Oct 2, 2017 07:11AM
Oct 2, 2017 07:00AM Asterias Announces Two Significant Developments for Spinal Cord Injury Program
Sep 25, 2017 07:00AM
Sep 14, 2017 05:44PM
Sep 14, 2017 05:43PM
Aug 30, 2017 07:00AM
Aug 23, 2017 07:00AM
Aug 14, 2017 04:10PM
Aug 14, 2017 07:00AM BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
Aug 9, 2017 07:00AM

251,551 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All